Chen Chia-Min, Chi Yunchan, Chang Hsing-Ming
a Department of Natural Biotechnology , Nanhua University , Dalin Township , Chiayi County , Taiwan R.O.C.
b Department of Statistics , National Cheng Kung University , Tainan City , Taiwan R.O.C.
J Biopharm Stat. 2018;28(5):939-950. doi: 10.1080/10543406.2018.1428615. Epub 2018 Jan 22.
In phase II clinical trials, patients are recruited sequentially and consequently the time required to complete the clinical trial will become long if the accrual rate is low. To speed up the drug development process and account for ethical issues, stochastically and non-stochastically curtailed two-stage designs have been proposed in single-arm phase II clinical trials. More recently, randomized phase II clinical trials are being increasingly recommended to avoid biased evaluation of the treatment effect when compared with a historical control. The current patient population and the historical one may be quite heterogeneous. Moreover, it is impossible to randomly assign patients for treatments. Consequently, various two-stage designs have been presented for comparing two arms. Since the sample size required in a randomized phase II trial is usually larger than that required in a single-arm phase II trial, we introduce the concept of curtailed sampling procedure to develop curtailed two-stage design for two-armed, randomized phase II clinical trials. The proposed design does not require pairwise patient response comparison, yet it allows a trial to be stopped early as soon as the difference in therapeutic effect of the experimental therapy and the standard at the end of a trial is foreknown.
在II期临床试验中,患者是按顺序招募的,因此如果入组率较低,完成临床试验所需的时间就会变长。为了加快药物研发进程并考虑伦理问题,在单臂II期临床试验中提出了随机和非随机截尾的两阶段设计。最近,越来越多的人推荐采用随机II期临床试验,以便与历史对照相比时避免对治疗效果进行有偏评估。当前的患者群体和历史患者群体可能差异很大。此外,不可能随机分配患者进行治疗。因此,已经提出了各种两阶段设计来比较两个治疗组。由于随机II期试验所需的样本量通常大于单臂II期试验所需的样本量,我们引入截尾抽样程序的概念,为双臂随机II期临床试验开发截尾两阶段设计。所提出的设计不需要对患者反应进行成对比较,但一旦在试验结束时已知实验治疗与标准治疗的疗效差异,就允许试验尽早停止。